Condition (MeSH)
Factor X Deficiency
ClinicalTrials.gov lists 6 trials for Factor X Deficiency or a narrower condition beneath it. Kedrion S.p.A. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Factor X Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Factor X Deficiency trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2018 | 2 |
| 2015 | 1 |
| 2011 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Factor X Deficiency trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 4 |
| Observational | 2 |
How many Factor X Deficiency trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 3 |
| Terminated | 1 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Factor X Deficiency trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kedrion S.p.A. | 1 |
Which serious adverse events do Factor X Deficiency trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anaemia | 2 | 1 |
| Back pain | 1 | 1 |
| Dysmenorrhoea | 1 | 1 |
| Gastric ulcer helicobacter | 1 | 1 |
| Gastritis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Factor X Deficiency? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. | Transfusion | 2023 | Yes |
| Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency. | Experimental & molecular medicine | 2021 | Yes |
| Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study. | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2018 | Yes |
| Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. | Journal of thrombosis and haemostasis : JTH | 2004 | No |
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital factor X deficiency | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Congenital factor X deficiency | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital factor X deficiency | 328 | Exact | Orphadata Science knowledge files, Product 1 |
| Congenital factor X deficiency | 328 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.